Related by context. All words. (Click for frequent words.) 70 dosing cohort 70 dose cohort 70 dose escalation 68 relapsed MM 68 sitaxsentan 67 CIMZIA TM 67 phase Ib 67 budesonide foam 67 APTIVUS r 67 riociguat 67 dose titration 67 STRIDE PD 66 Phase #b/#a 66 HCV RESPOND 2 66 dose escalation phase 66 ascending dose 66 RSD# oral 66 virological failure 65 treatment naive genotype 65 maximal doses 65 titration phase 65 maximally tolerated dose 65 DSMB recommended 65 DLTs 65 alvespimycin 65 PROMACTA 65 #mg/day [002] 65 Phase Ib study 65 PSMA ADC 65 APTIVUS 65 phase IIb clinical 65 XL# SAR# 65 R#/MEM # 65 mg/m2 cohort 65 BYSTOLIC 65 forodesine 64 dose escalation Phase 64 Bezielle 64 Phase Ib clinical 64 oral rivaroxaban 64 blinded randomized placebo controlled 64 Phase Ib II 64 phase IIb trial 64 hematologic toxicity 64 PegIFN RBV 64 Fibrillex TM 64 serum phosphorous 64 mg kg dose 64 MAGE A3 ASCI 64 EMPHASIS HF trial 64 phase Ib clinical 64 imatinib therapy 64 INCB# [001] 64 elotuzumab 64 CIMZIA ™ 64 tolerated dose MTD 64 trastuzumab Herceptin ® 63 ZOLINZA 63 Elocalcitol 63 OPT CHF 63 #mg/m# [002] 63 Maximum Tolerated Dose MTD 63 multicenter randomized placebo controlled 63 Maximum Tolerated Dose 63 confirmatory clinical 63 antihypertensive therapy 63 treprostinil 63 pharmacokinetic interactions 63 CHAMPION PCI 63 glatiramer acetate 63 Phase IIIb clinical 63 phase IIb 63 KAPIDEX 63 rindopepimut 63 VIRAMUNE XR 63 BRIM3 63 mg/m2 dose 63 DAPT 63 pharmacodynamic effects 63 Phase 1b trial 63 dosing cohorts 63 HGS# 63 AGILECT R 63 oral methylnaltrexone 63 placebo controlled clinical 63 Phase IIB 63 estramustine 63 peginterferon 63 refractory CLL 63 Phase #b/#a trial 63 aplindore 63 Teriflunomide 63 androgen suppression 63 neurologic progression 63 peg interferon 63 ACTIVE W 62 divalproex sodium 62 Phase 2a trial 62 torezolid phosphate 62 oral ridaforolimus 62 tolvaptan 62 sunitinib 62 galiximab 62 HCD# [002] 62 PEARL SC 62 midstage clinical 62 ATACAND 62 Tarceva TM 62 HCV SPRINT 62 AZOR 62 lesinurad 62 lomitapide 62 dosing interval 62 prucalopride 62 4mg/kg 62 insulin detemir 62 Aflibercept 62 cART 62 YONDELIS 62 rFVIIa 62 Subgroup analysis 62 Traficet EN 62 pomalidomide 62 virologic failure 62 IMPACT DCM 62 azilsartan medoxomil 62 ISTODAX 62 docetaxel chemotherapy 62 anthracycline taxane 62 clinical pharmacology studies 62 methotrexate therapy 62 MDS AML 62 antiretroviral naive 62 H. pylori eradication 62 thorough QT 62 desvenlafaxine succinate 62 phase IIa 62 R# #mg BID 62 HuMax CD4 62 pharmacokinetic PK study 62 Phase 2b study 62 fosbretabulin 62 ADAGIO study 62 Phase IIb clinical trials 62 PREZISTA r 62 posaconazole 62 NATRECOR R 62 mapatumumab 62 Hydroxyurea 62 Fulvestrant 62 MULTAQ 62 ZALBIN dosed 62 NATRECOR ® 62 antiandrogen 62 telaprevir dosing 62 nonrandomized 62 subgroup analyzes 62 relapsed MCL 62 AZILECT R 62 double blinded placebo 62 ADVANCE PD 62 elacytarabine 61 randomized multicenter Phase III 61 doxorubicin docetaxel 61 Primary endpoints 61 lipid lowering therapy 61 clevidipine 61 nitrofurantoin 61 acute mania 61 RSD# 61 dosage regimens 61 FAMPYRA 61 relapsed AML 61 nab paclitaxel 61 epoetin alpha 61 prospectively stratified 61 hour bronchodilation 61 midstage trials 61 piperacillin tazobactam 61 enzastaurin 61 Triapine R 61 EDEMA3 trial 61 brivaracetam 61 randomized Phase IIb 61 placebo controlled Phase 61 dexpramipexole 61 multicenter Phase 61 immunomodulatory therapy 61 PROCRIT therapy 61 nonclinical studies 61 LEP ETU 61 pyrazinamide 61 intermittent dosing 61 IIa trial 61 ACTEMRA TM 61 IMPACT DCM clinical 61 Toremifene 61 pivotal bioequivalence 61 IV bolus 61 AIM HIGH 61 SPRYCEL ® 61 Omacetaxine 61 decitabine 61 Phase #/#a 61 Phase IIa trials 61 ENGAGE AF TIMI 61 motesanib 61 doxorubicin cyclophosphamide 61 receptor tyrosine kinase inhibitor 61 plasma pharmacokinetics 61 GLP toxicology studies 61 Cloretazine 61 velafermin 61 #mg QD [001] 61 corticosteroid dose 61 ascending doses 61 oral deforolimus 61 plasma uric acid 61 Dextofisopam 61 multicenter Phase II 61 ATL# [001] 61 CLORETAZINE TM VNP#M 61 Tekamlo 61 Degarelix 61 BENICAR HCT 61 Ceplene/IL-2 61 Hypotension 61 flutamide 61 atazanavir ritonavir 61 Androxal TM 61 Certolizumab 61 SYMMETRY trial 61 Phase 1b 61 assessing T DM1 61 salmeterol fluticasone 61 COSIRA trial 61 multiple ascending dose 61 dose escalation clinical 61 Oral corticosteroids 61 baminercept 61 bolus injection 61 HGS ETR2 61 urocortin 2 61 dacetuzumab 61 tolevamer 61 AZILECT ® 61 Stedivaze 61 muraglitazar 61 INCB# [003] 61 HGS ETR1 61 bicifadine 61 TACI Ig 60 nitazoxanide 60 farletuzumab 60 #mg dose [002] 60 Panzem R NCD 60 blastic phase 60 Diamyd r vaccine 60 recurrent glioma 60 vitamin B# folic acid 60 COU AA 60 favorable pharmacokinetic profile 60 prospectively defined 60 lenalidomide Revlimid R 60 samalizumab 60 vicriviroc 60 Enzastaurin 60 HIV HCV coinfected 60 placebo controlled clinical trials 60 Dasatinib 60 tamoxifen therapy 60 LibiGel Phase III 60 irbesartan 60 bavituximab monotherapy trial 60 Eltrombopag 60 mertansine 60 RESIST studies 60 CA4P 60 teriflunomide 60 pharmacokinetic PK 60 PRE SURGE 60 TDF FTC 60 ELACYT 60 eculizumab therapy 60 suppressive therapy 60 Phase Ib 60 Arikace 60 Sustained Virological Response 60 HBeAg seroconversion 60 deferiprone 60 ARIKACE 60 postoperative chemotherapy 60 pharmacodynamics PD 60 visilizumab 60 serum urate levels 60 ibandronate 60 tramiprosate Alzhemed TM 60 dose cohorts 60 LUMINATE 60 Motesanib 60 olaparib 60 bronchodilation 60 Laquinimod 60 icatibant 60 GLP1 agonist 60 Non inferiority 60 ALT flares 60 Phase III Pivotal 60 sustained virologic response 60 Phase #b/#a clinical 60 EXJADE 60 Ophena TM 60 serum phosphate levels 60 mTOR inhibition 60 anti leukemic 60 paclitaxel poliglumex 60 GSK# [001] 60 evaluable subjects 60 Aplidin 60 PEG SN# 60 MGd 60 pegaptanib 60 ENESTnd 60 CALGB # [001] 60 TMC# C# 60 Phase IIa trial 60 virological response 60 huN# DM1 60 pharmacodynamic PD 60 Pivotal Phase 60 Ozarelix 60 anagrelide 60 #mg/m# [001] 60 weekly subcutaneous injections 60 rALLy trial 60 Zemplar Capsules 60 PRADAXA 60 heavily pretreated 60 PEG IFN 60 Hepatocellular Carcinoma HCC 60 MERLIN TIMI 60 intravenous dosing 60 DEB# 60 Saxagliptin 60 Phase 1a 60 TBC# 60 MEND CABG 60 EDARBI 60 lumiliximab 60 viral kinetics 60 novel VDA molecule 60 GnRH agonist 60 interferon ribavirin 60 recurrent glioblastoma multiforme 60 phase IIIb 60 GENASIS trial 60 pyridostigmine 60 GOUT 60 eosinophilic asthma 60 phase IIb study 60 APTIVUS ritonavir 60 dose escalation trial 60 subcutaneous enoxaparin 60 LCP Tacro TM 60 dose limiting toxicities 60 avosentan 60 NVA# 60 OHR/AVR# 60 gout flares 60 CANCIDAS 60 registrational 60 FOLPI 60 HAART regimens 59 mg administered orally 59 ANCHOR trial 59 Elitek 59 phase IIa clinical 59 LEXIVA r 59 VP# [004] 59 PRIMO CABG 59 secondary efficacy endpoint 59 peak plasma concentrations 59 eritoran 59 Talotrexin 59 mg/m2 administered 59 Poly ICLC 59 EVIZON 59 treatment naïve genotype 59 alkylating agent 59 Darusentan 59 recurrent VTE 59 mg/m2/day 59 Xelox 59 cilostazol 59 evaluating mipomersen 59 #mg QD [002] 59 Zevalin consolidation 59 Randomized Phase II 59 maximal tolerated 59 Pharmacokinetic parameters 59 Cethromycin 59 #.#g/day 59 SVR# 59 solithromycin 59 RE LY ® 59 PRECISE Trial 59 EMEND 59 DDP# 59 detectable HCV RNA 59 #mg dose [003] 59 Phase Ib clinical trials 59 mesalamine granules 59 ritonavir boosted protease inhibitor 59 GAMMAGARD 59 MEND CABG II 59 serum phosphate 59 tesmilifene 59 TYGACIL 59 alteplase 59 idarubicin 59 IMC A# 59 β blockers 59 Randomized Phase 59 Hormone Refractory Prostate Cancer 59 phase IIb III 59 aminotransferase levels 59 ELND# 59 timepoint 59 BEACOPP 59 Bortezomib 59 multicenter placebo controlled 59 beta blocker therapy 59 PROSTVAC ® 59 administered subcutaneously 59 refractory AML 59 PAOD 59 FOLPI regimen 59 Tocosol Paclitaxel 59 Virulizin ® 59 antidepressant therapy 59 ribavirin RBV 59 CR nPR 59 LATUDA 59 OADs 59 cannabinor 59 LHRH agonists 59 Folfox 59 COPAXONE 59 ritonavir boosted 59 alicaforsen enema 59 CIMZIA TM certolizumab pegol 59 virologic response 59 overt nephropathy 59 ULORIC 59 CALGB # [002] 59 Sapacitabine 59 pimozide 59 Pegloticase 59 BAY #-# 59 efficacy endpoint 59 CTAP# Capsules 59 abiraterone acetate 59 ASSERT trial 59 cisplatin vinorelbine 59 ANAVEX #-# [001] 59 SUTENT 59 ganetespib 59 EGFR TKI 59 Decitabine 59 enalapril 59 dorzolamide 59 goserelin 59 QT QTc 59 morphometric vertebral fractures 59 inhaled tobramycin 59 K ras mutations 59 blinded placebo controlled 59 VITAL Trial 59 #mg doses [002] 59 aminotransferases 59 SIMPADICO 59 REVIVE Diabetes 59 arbaclofen 59 ORENCIA ® 59 orBec 59 mesilate 59 opioid bowel dysfunction 59 Symadex 59 albiglutide 59 mCi kg 59 relapsed ALL 59 oral FTY# 59 montelukast 59 metastatic HRPC 59 Phase IIA 59 recurrent malignant glioma 59 CAPACITY trials 59 gefitinib Iressa 59 BEXXAR 59 Prodarsan 59 tocilizumab 59 pegylated interferon alpha 59 daily subcutaneous injections 59 elevated ALT 59 Decompensated Heart Failure 59 ARCOXIA 59 NNRTI resistance 59 active comparator 59 leflunomide 59 tipranavir r 59 NNRTI 59 Cohort Study MACS 59 Febrile neutropenia 59 statin monotherapy 59 subcutaneous infusion 59 Phase 2b trial 59 Deforolimus 59 CytoFabTM 59 9mg 59 VAPRISOL 59 QTc prolongation 59 renal toxicity 59 oral prednisone 59 HF ACTION 59 masked placebo controlled 59 HBV infections 59 CCX# 59 DOXIL 59 tanespimycin 59 Pemetrexed 59 oral prednisolone 59 olmesartan 59 iPTH 59 dexanabinol 59 unblinded 59 biologic DMARD 59 bolus dose 59 ponatinib 59 Nilotinib 59 GFT# 59 Forodesine HCl 59 gadobutrol 59 comparator arm 59 LB# [003] 59 radiochemotherapy 59 registrational trial 59 Prostate AdenoCarcinoma Treatment 59 FOLFIRI 59 adalimumab 59 ertapenem 59 Phase IIb trials 59 ziconotide 59 TLK# 59 dose proportionality 59 im peramivir 59 Natalizumab 59 mRCC 59 EDEMA3 59 Archexin 59 QLT# 59 warfarin therapy 59 LY# [003] 59 vandetanib 59 steroid dexamethasone 59 iniparib BSI 59 pentoxifylline 59 rapid virologic response 59 nucleotide analog 58 uric acid lowering 58 fluvastatin 58 PrandiMet TM 58 Lixivaptan 58 RLAI 58 Phase Ia 58 XEPLION R 58 ALT elevations 58 Diamyd r 58 ADHF 58 PRIMO CABG2 58 AQ4N 58 IFN beta 58 subcutaneous dose 58 JAK inhibitors 58 certolizumab 58 RE LY 58 CAMMS# 58 low dose cytarabine 58 Cloretazine R VNP#M 58 dexamethasone Decadron 58 allogeneic HSCT 58 Insulin PH# 58 BETAS 58 alpha blocker 58 aflibercept VEGF Trap 58 COPAXONE R 58 pegylated IFN 58 8mg/kg 58 dose regimens 58 Glypromate 58 antithrombotic therapy 58 induce remission 58 corticosteroid dexamethasone 58 IMC #B 58 interferon gamma 1b 58 TNF antagonist 58 squalamine 58 paricalcitol 58 ILLUMINATE 58 prospective observational cohort 58 ruboxistaurin 58 randomized Phase 2b 58 IFN α 58 antitumor effect 58 acyclovir Lauriad R 58 Phase 1a clinical 58 placebo controlled trials 58 invasive aspergillosis 58 CALGB 58 nephrotoxicity 58 Aptivus ® 58 adrenal suppression 58 q#h 58 sunitinib malate 58 AKT inhibitor 58 TORISEL 58 pelvic lymphadenectomy 58 noninferiority 58 KOMBIGLYZE XR 58 dopaminergic therapy 58 paclitaxel Taxol R 58 recurrent metastatic 58 Phase Ib IIa 58 Anturol TM 58 genotypic resistance 58 #mg dose [001] 58 ABSORB trial 58 corrected QT interval 58 AeroLEF TM 58 balsalazide 58 oxypurinol 58 adjunctive placebo 58 PEGylated interferon beta 1a 58 corticosteroid therapy 58 biliary tract cancer 58 Retreatment 58 AEGR 58 mg TID 58 alefacept 58 Methylnaltrexone 58 Phase 1b clinical trials 58 pioglitazone HCl 58 Phase IIb III 58 chemoradiotherapy 58 refractory NSCLC 58 curative resection 58 Capesaris 58 Candesartan 58 Pazopanib 58 CD4 + cell 58 HBeAg negative 58 ocrelizumab 58 intensive statin therapy 58 clomipramine 58 chemotherapy docetaxel 58 compound INCB# 58 lymph node dissection 58 AIR CF1 58 mg RDEA# 58 cerebral vasospasm 58 axitinib 58 CEQ# 58 BEXXAR Therapeutic Regimen 58 Orazol 58 opioid induced bowel dysfunction 58 ZACTIMA 58 Tanespimycin 58 refractory multiple myeloma 58 analgesic efficacy 58 rasagiline 58 Raptiva r 58 Pivotal Phase III 58 hypercalcemia 58 EGFRIs 58 Toxicities 58 Proellex TM 58 ARIMIDEX 58 Q#IR 58 dose dose escalation 58 venlafaxine XR 58 mg dose 58 alpha#beta# integrin 58 JAK inhibitor 58 cilengitide 58 Mipomersen 58 bile duct tumor 58 Aortic Stenosis 58 BRIM2 58 refractory cutaneous T 58 PRTX 58 PREVENT IV 58 Plicera 58 intravenous CK # 58 efalizumab 58 CIMZIA R 58 insulin degludec 58 APRISO 58 mg BID dose 58 postintervention 58 INTERCEPT platelets 58 intensive lipid lowering 58 valopicitabine 58 VIRAMUNE 58 telaprevir dosed 58 DCCR 58 HAART regimen 58 protease inhibitor PI 58 Arranon 58 PRADAXA #mg 58 SNT MC# 58 PSN# [002] 58 XmAb# 58 VIIBRYD 58 COREG 58 APPRAISE 58 Tipranavir 58 Ataluren 58 randomized multicenter trial 58 selective modulator 58 TRO# 58 Uricase PEG 58 metastatic GIST 58 mGluR5 NAM 58 F FDG PET 58 Xanafide 58 non nucleoside HCV 58 VFEND 58 eltrombopag 58 Torisel 58 serum uric acid 58 Azacitidine 58 bevirimat Study 58 demonstrated antitumor activity 58 AZILECT 58 SIMCOR 58 prospective randomized placebo 58 APEX PD 58 intravenous bisphosphonates 58 bisoprolol 58 ropinirole 58 viral kinetic 58 Blinatumomab 58 superficial bladder cancer 58 cMET 58 Onrigin 58 urate lowering therapy 58 Aclidinium 58 guanfacine extended release 58 cardiac toxicity 58 Apixaban 58 CYT# QbG# 58 vidofludimus 58 insulin glulisine 58 Nuvion 58 DSMB 58 pegylated interferon alfa 58 QVA# 58 MIRCERA 58 triple nucleoside 58 dasatinib 58 bezafibrate 58 ispinesib administered 58 BLA filing 58 rhEPO 58 nicardipine 58 Golimumab 58 Platinol ® 58 aspartate aminotransferase 58 crizotinib PF # 58 MGCD# [001] 58 OMP #R# 58 candesartan cilexetil 58 aspartate aminotransferase AST 58 plasma kallikrein inhibitor 58 complete cytogenetic response 58 macroalbuminuria 58 galantamine 58 bioequivalency 58 platinum refractory 58 rechallenge 58 alvimopan 58 Phase III Clinical Trial 58 HBeAg 58 Betaferon R 58 octreotide LAR 58 efavirenz EFV 58 Dacogen injection 58 HuMax EGFr 58 ara C 58 PF # [002] 58 dirucotide 58 sitagliptin 58 ABC/3TC 58 eniluracil 58 relapsed refractory multiple myeloma 58 Nesiritide 58 mg BID 58 RRMS patients 58 Board DSMB 58 CrCl 58 pharmacokinetic characteristics 58 cytotoxic therapy 58 EndoTAG TM -1 58 trastuzumab DM1 58 eplerenone 58 dose cyclophosphamide 58 NP2 Enkephalin 58 poststroke depression 58 PIX# [002] 58 systemic corticosteroid 58 ACAPODENE 58 ancrod 58 Serdolect ® 58 MADIT II 58 abacavir lamivudine 58 rFSH 58 LPV r 58 PROPEL trial 58 balsalazide tablet 58 Lofexidine 58 PEGINTRON TM 58 Velcade bortezomib 58 Dr. Chenchen Wang 58 Azedra 58 OMP #M# 58 azacitidine 58 indibulin 58 continuous intravenous infusion 58 Double Blind Randomized 58 LANTUS R 58 Telintra 58 abatacept 58 BR.# 58 VA# [002] 58 Kinoid 58 SSRI SNRI 58 Cytoxan 58 Phase lll 58 serum testosterone 58 ® pioglitazone HCl 58 rolofylline 58 Doxil ® 58 Mylotarg 58 celgosivir 58 venlafaxine ER 58 PFO migraine 58 FOSRENOL ® 58 MYLOTARG 58 RhuDex 58 DMARD therapy 57 Bicifadine 57 EOquin TM 57 PXD# 57 Triolex 57 urate lowering 57 CRp 57 hematological toxicity 57 antibody titer 57 tumor necrosis 57 adriamycin 57 surgical debulking 57 voriconazole 57 Viprinex 57 hypercholesterolemic patients 57 diabetic gastroparesis 57 REMINYL ® 57 cabazitaxel 57 omega interferon 57 randomized multicentre 57 interferon beta therapy 57 cangrelor 57 Dose adjustments 57 Perforomist Inhalation Solution 57 cisplatin chemotherapy 57 RLY# 57 CRESTOR #mg 57 pharmacokinetic parameters 57 Pafuramidine 57 TELCYTA 57 QD dosing 57 naïve HCV 57 Initiate Phase 57 hepatotoxicity 57 perioperatively 57 INTELENCE 57 Postoperative complications 57 aleglitazar 57 Zoledronic acid 57 Tumor Response 57 perampanel 57 tasisulam 57 rEV# 57 evaluating tivozanib 57 iclaprim 57 MIST II 57 chlorambucil 57 evaluating Actimmune 57 Sitagliptin 57 CML CP 57 rALLy clinical trial 57 somatostatin analog 57 controlled multicenter 57 CBLC# 57 ToGA 57 ALGRX 57 q8h 57 placebo controlled randomized 57 serum urate 57 Myelodysplastic Syndrome MDS 57 taxane chemotherapy 57 Urocortin 2 57 colesevelam HCl 57 cis retinoic acid 57 mycophenolate mofetil 57 Tyrima 57 CR# vcMMAE 57 dose proportional pharmacokinetics 57 periprocedural 57 edoxaban 57 INFERGEN 57 IIa trials 57 HoFH 57 deforolimus 57 multicenter randomized controlled 57 Betaferon ® 57 AZT zidovudine Retrovir 57 BARACLUDE ® 57 serum HBV DNA 57 omacetaxine mepesuccinate 57 CLARITY study 57 CHOP chemotherapy 57 Committee IDMC 57 PD LID 57 opioid analgesia 57 aflibercept 57 moderate hepatic impairment 57 TTF Therapy 57 GnRH antagonist 57 Viramidine 57 Phase 2a clinical trials 57 pharmacokinetic studies 57 platelet inhibitor 57 TMC# r 57 tenofovir emtricitabine 57 null responder HCV 57 Hepatotoxicity 57 strong CYP#A# inducers 57 calcineurin inhibitor 57 herpetic keratitis 57 bosutinib 57 concomitant medications 57 rilonacept 57 MAS XR 57 fluticasone furoate 57 HbA 1c levels 57 ritonavir boosting 57 rHuEPO 57 concurrent chemoradiation 57 metastatic RCC 57 Mg Usa 57 Phase III randomized controlled 57 peginterferon alfa 57 diabetic neuropathic pain 57 LUX Lung 57 solifenacin 57 PANVAC VF 57 Safinamide 57 Known hypersensitivity 57 histologic subtype 57 tinzaparin 57 nephrotoxic drugs 57 Adjuvant chemotherapy 57 GRAVITAS trial 57 MoxDuo TM IR 57 randomized blinded 57 tarenflurbil 57 inecalcitol 57 papillary renal cell carcinoma 57 oral allopurinol 57 Actilon 57 intravenous bolus 57 pharmacokinetics PK 57 Lenocta 57 blinded randomized 57 Eligen R B# 57 antiretroviral regimen 57 bepotastine besilate nasal spray 57 FOLFOX4 57 GSK# [002] 57 empiric therapy